Abstract:Background: Ovarian cancer has poor survival due to more than 60% of patients being diagnosed at advanced stage. Therefore, discovery of novel, non-invasive early detection biomarkers has high potential to improve survival. Here, we identified plasma metabolomic profiles associated with early-stage and late-stage high-grade serous ovarian cancer (HGSOC), the most common histotype. Method: We examined 197 lipid and lipid-related metabolites measured using a validated, liquid chromatography tandem mass spectrometry method (Broad Institute, Cambridge, MA) in plasma collected prior to surgery from 40 early-stage and 40 late-stage HGSOC patients and 40 population-based controls matched on age, year, and menopausal status at blood draw. We used multivariable logistic regression, adjusted for matching factors, tubal ligation, oral contraceptive use, and parity, to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) of ovarian cancer risk per 1 standard deviation increase in probit-transformed metabolite levels. We used Metabolite Set Enrichment Analysis (MSEA) to identify metabolite groups. We accounted for testing multiple correlated hypotheses using the number of effective tests (NEF) or false discovery rate (FDR). Results: Compared to controls, there were 34 metabolites associated with early-stage HGSOC and 88 metabolites associate with late-stage HGSOC (unadjusted p-value<0.05). All metabolites associated with risk of early-stage HGSOC and majority (n=80, 90%) of the metabolites associated with risk of late-stage HGSOC were inversely associated with ORs ranging from 0.28 to 0.48 for early-stage and 0.08 to 0.59 for late-stage HGSOC. Interestingly, the direction of association across all these metabolites were similar in both early-stage and late-stage HGSOC, with stronger effect estimates for late-stage HGSOC. After multiple testing correction, there were 9 statistically significant metabolites associated with risk of late-stage HGSOC (NEF p-value<0.05) whereas no individual metabolites remained associated with risk of early-stage HGSOC. MSEA revealed similar patterns of association compared to controls across the 11 lipid groups assessed in early and late-stage HGSOC cases. Metabolite groups of phosphatidylethanolamine plasmalogens and triglycerides were inversely associated with early-stage HGSOC compared to controls (FDR p-value<0.05). Metabolite groups of phosphatidylethanolamine plasmalogens and phosphatidylcholines were inversely, and diglycerides were positively associated with late-stage HGSOC compared to controls (FDR p-value<0.05). Conclusion: Our results revealed early-stage and late-stage HGSOC having similar plasma metabolomic profiles overall although there were more metabolites that were significantly associated with late-stage HGSOC than early-stage HGSOC compared to population-based controls. Citation Format: Naoko Sasamoto, Oana A. Zeleznik, Allison F. Vitonis, Daniel W. Cramer, Julian Avila-Pacheco, Clary B. Clish, Shelley S. Tworoger, Kathryn L. Terry. Plasma metabolomic profiles associated with early and late-stage high-grade serous ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2253.

Metabolomic Analysis of Histological Composition Variability of High-Grade Serous Ovarian Cancer Using 1H HR MAS NMR Spectroscopy

Metabolic characterization of primary and metastatic ovarian cancer by 1H-MRS in vivo at 3T

Metabolomic analysis of endometrial cancer by high-resolution magic angle spinning NMR spectroscopy

Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy

Metabolic Portraits of Breast Cancer by HR MAS MR Spectroscopy of Intact Tissue Samples

Profiling of metabolic dysregulation in ovarian cancer tissues and biofluids

Study of Metabonomic Profiles of Human Esophageal Carcinoma by Use of High-Resolution Magic-Angle Spinning 1H NMR Spectroscopy and Multivariate Data Analysis

Metabonomic Studies of Human Hepatocellular Carcinoma Using High-Resolution Magic-Angle Spinning 1H NMR Spectroscopy in Conjunction with Multivariate Data Analysis.

High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy of Paired Clinical Liver Tissue Samples from Hepatocellular Cancer and Surrounding Region

Metabolomic Analysis of Amino Acid and Organic Acid Profiles in Tissue From Ovarian Cancer Patients Using High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS) and Gas Chromatography-Tandem Mass Spectrometry (GC-MS/MS)

Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma

Serum free amino acid profiling in differential diagnosis of ovarian tumors – a case control study with review of the literature

Space- and Time-Resolved Metabolomics of a High-Grade Serous Ovarian Cancer Mouse Model

Metabolomics of Breast Cancer Using High-Resolution Magic Angle Spinning Magnetic Resonance Spectroscopy: Correlations with 18F-FDG Positron Emission Tomography-Computed Tomography, Dynamic Contrast-Enhanced and Diffusion-Weighted Imaging MRI

Mass spectrometric profiling reveals association of N-glycan patterns with epithelial ovarian cancer progression.

Urinary Hydrophilic and Hydrophobic Metabolic Profiling Based on Liquid Chromatography-Mass Spectrometry Methods: Differential Metabolite Discovery Specific to Ovarian Cancer

Targeted Microchip Capillary Electrophoresis-Orbitrap Mass Spectrometry Metabolomics to Monitor Ovarian Cancer Progression

Ultrahigh resolution lipid mass spectrometry imaging of high-grade serous ovarian cancer mouse models

Abstract 2253: Plasma metabolomic profiles associated with early and late-stage high-grade serous ovarian cancer

Rapid Discrimination of Human Oesophageal Squamous Cell Carcinoma by Mass Spectrometry Based on Differences in Amino Acid Metabolism

Malignancy-associated metabolic profiling of human glioma cell lines using 1 H NMR spectroscopy